A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients

• Status: Completed
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Objective of this study is to evaluate the safety, tolerability, pharmacokinetics and preliminary pharmacodynamic effects of multiple doses of Gantenerumab in subject with mild to moderate AD.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chugai Pharmaceutical
• Treatments: Antibodies, Monoclonal

Criteria

Inclusion Criteria:

• Have a diagnosis of probable AD dementia, based on NINCDS/ADRDA criteria

• Meet DSM-IV criteria for Dementia of the Alzheimer type

• MMSE score : 16 to 26 etc.

Exclusion Criteria:

• Meet the exclusion criteria of MRI at screening.

• A history of significant neurodegenerative diseases or dementia other than Alzheimer's disease.

etc.